ARMP (Armata Pharmaceuticals) Risk Assessment


ARMP Armata Pharmaceuticals Inc ARMP
27 GF Score
Price $5.89
! 3 Warning Signs
View Full Analysis

What is Armata Pharmaceuticals Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Armata Pharmaceuticals is: No Data: Cannot be evaluated.

Armata Pharmaceuticals  (AMEX:ARMP) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Armata Pharmaceuticals Risk Assessment Related Terms

ARMP vs NAGE, ALXO, LYEL: Risk Assessment Comparison

For the Biotechnology subindustry, Armata Pharmaceuticals's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Armata Pharmaceuticals Risk Assessment vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Armata Pharmaceuticals's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Armata Pharmaceuticals's Risk Assessment falls into.


ARMP
27GF Score
Armata Pharmaceuticals Inc ARMP
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Armata Pharmaceuticals Business Description

Other Exchanges TG1N:Germany
Address 5005 McConnell Avenue, Los Angeles, CA, USA, 90066
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
27GF Score

Get the complete analysis for ARMP

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.89
Price